Inventiva S.A. (IVA.PA)
EUR 2.82
(-0.53%)
EUR 2.82
(-0.53%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 69.13 Million EUR | -40.4% |
| 2022 | 116 Million EUR | -4.9% |
| 2021 | 121.98 Million EUR | -12.19% |
| 2020 | 138.92 Million EUR | 143.89% |
| 2019 | 56.96 Million EUR | -28.63% |
| 2018 | 79.81 Million EUR | 7.32% |
| 2017 | 74.36 Million EUR | 52.2% |
| 2016 | 48.85 Million EUR | -19.34% |
| 2015 | 60.57 Million EUR | -17.17% |
| 2014 | 73.13 Million EUR | -16.05% |
| 2013 | 87.11 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q4 | 69.13 Million EUR | 0.0% |
| 2023 FY | 69.13 Million EUR | -40.4% |
| 2023 Q2 | 70.81 Million EUR | 0.0% |
| 2022 FY | 116 Million EUR | -4.9% |
| 2022 Q2 | 108.39 Million EUR | 0.0% |
| 2022 Q4 | 116 Million EUR | 0.0% |
| 2021 FY | 121.98 Million EUR | -12.19% |
| 2021 Q1 | 132.22 Million EUR | -4.82% |
| 2021 Q2 | 117.21 Million EUR | -11.35% |
| 2021 Q4 | 121.22 Million EUR | 0.0% |
| 2020 FY | 138.92 Million EUR | 143.89% |
| 2020 Q2 | 68.72 Million EUR | 0.0% |
| 2020 Q4 | 138.92 Million EUR | 0.0% |
| 2019 Q4 | 56.96 Million EUR | 0.0% |
| 2019 FY | 56.96 Million EUR | -28.63% |
| 2019 Q2 | 61.04 Million EUR | 0.0% |
| 2018 Q4 | 79.81 Million EUR | 0.0% |
| 2018 FY | 79.81 Million EUR | 7.32% |
| 2018 Q2 | 95.79 Million EUR | 0.0% |
| 2017 FY | 74.36 Million EUR | 52.2% |
| 2017 Q4 | 74.36 Million EUR | 0.0% |
| 2017 Q2 | 81.45 Million EUR | 0.0% |
| 2016 Q4 | 48.85 Million EUR | 0.0% |
| 2016 FY | 48.85 Million EUR | -19.34% |
| 2016 Q2 | 54.14 Million EUR | 0.0% |
| 2015 FY | 60.57 Million EUR | -17.17% |
| 2015 Q4 | 60.57 Million EUR | 0.0% |
| 2014 FY | 73.13 Million EUR | -16.05% |
| 2013 FY | 87.11 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -370.014% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 78.861% |
| Adocia SA | 24.95 Million EUR | -177.044% |
| Aelis Farma SA | 26.28 Million EUR | -163.076% |
| Biophytis S.A. | 11.93 Million EUR | -479.248% |
| Advicenne S.A. | 12.4 Million EUR | -457.258% |
| genOway Société anonyme | 31.84 Million EUR | -117.129% |
| IntegraGen SA | 8 Million EUR | -764.2% |
| Medesis Pharma S.A. | 1.92 Million EUR | -3489.147% |
| Neovacs S.A. | 47.53 Million EUR | -45.453% |
| NFL Biosciences SA | 3.97 Million EUR | -1641.261% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -363.618% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -1745.296% |
| Sensorion SA | 46.49 Million EUR | -48.705% |
| Theranexus Société Anonyme | 7.23 Million EUR | -855.257% |
| TME Pharma N.V. | 2.49 Million EUR | -2675.552% |
| Valbiotis SA | 33.24 Million EUR | -107.949% |
| TheraVet SA | 7.53 Million EUR | -817.67% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -96.006% |
| DBV Technologies S.A. | 165.65 Million USD | 58.262% |
| Genfit S.A. | 173.87 Million EUR | 60.236% |
| GeNeuro SA | 6.31 Million EUR | -995.202% |
| Innate Pharma S.A. | 184.19 Million EUR | 62.464% |
| MaaT Pharma SA | 42.93 Million EUR | -61.047% |
| MedinCell S.A. | 36.94 Million EUR | -87.125% |
| Nanobiotix S.A. | 93.89 Million EUR | 26.367% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 15.581% |
| Poxel S.A. | 4.82 Million EUR | -1333.527% |
| GenSight Biologics S.A. | 9.08 Million EUR | -660.856% |
| Transgene SA | 45.21 Million EUR | -52.905% |
| Valneva SE | 469.39 Million EUR | 85.27% |